Inês Pereira1,2, Alexandre Valentim-Lourenço3, Catarina Castro3, Inês Martins3, Alexandra Henriques3, Ana Luísa Ribeirinho3. 1. Department of Obstetrics, Gynecology, and Reproductive Medicine, Hospital de Santa Maria, Lisbon, Portugal. ines.ifpereira@gmail.com. 2. , Rua do Ebro N1 4°C, 1990-526, Lisboa, Portugal. ines.ifpereira@gmail.com. 3. Department of Obstetrics, Gynecology, and Reproductive Medicine, Hospital de Santa Maria, Lisbon, Portugal.
Abstract
INTRODUCTION AND HYPOTHESIS: Midurethral slings (MUS) are still discussed in complex incontinence situations, such as obesity, lacking sustained efficacy validation in this particular sub-population. We hypothesized that the outcomes of a transobturator MUS, such as TVT-O, do not differ according to body mass index (BMI) over a 4-year period. METHODS: We conducted a retrospective analysis of 281 women who underwent TVT-O at our institution, between 2004 and 2012. Patients were stratified into obese (BMI ≥ 30 kg/m(2)) or non-obese (BMI < 30 kg/m(2)). We compared preoperative and postoperative parameters, including objective cure (negative stress test), complications, and quality of life scores. Data were collected at 0, 6, 12, 24, and 48 months. We used Fisher's exact test for categorical variables and Student's t test or the Mann-Whitney U test for continuous variables. RESULTS: Baseline characteristics of the obese (n = 122) and non-obese groups (n = 159) were similar. We found no significant differences between groups in terms of objective cure rates at all follow-up evaluations, with 95.8 % and 95 % at 48 months in the non-obese and obese groups respectively. There were no significant differences in the cumulative complication rates of both groups. Quality of life assessment also showed no significant differences between groups at all follow-up visits. At 48 months our follow-up rate was 59 % (n = 96) and 60.4 % (n = 72) in the non-obese and obese group respectively (p = 0.9). CONCLUSIONS: The TVT-O procedure is effective and safe in the long term for stress incontinence treatment, regardless of BMI.
INTRODUCTION AND HYPOTHESIS: Midurethral slings (MUS) are still discussed in complex incontinence situations, such as obesity, lacking sustained efficacy validation in this particular sub-population. We hypothesized that the outcomes of a transobturator MUS, such as TVT-O, do not differ according to body mass index (BMI) over a 4-year period. METHODS: We conducted a retrospective analysis of 281 women who underwent TVT-O at our institution, between 2004 and 2012. Patients were stratified into obese (BMI ≥ 30 kg/m(2)) or non-obese (BMI < 30 kg/m(2)). We compared preoperative and postoperative parameters, including objective cure (negative stress test), complications, and quality of life scores. Data were collected at 0, 6, 12, 24, and 48 months. We used Fisher's exact test for categorical variables and Student's t test or the Mann-Whitney U test for continuous variables. RESULTS: Baseline characteristics of the obese (n = 122) and non-obese groups (n = 159) were similar. We found no significant differences between groups in terms of objective cure rates at all follow-up evaluations, with 95.8 % and 95 % at 48 months in the non-obese and obese groups respectively. There were no significant differences in the cumulative complication rates of both groups. Quality of life assessment also showed no significant differences between groups at all follow-up visits. At 48 months our follow-up rate was 59 % (n = 96) and 60.4 % (n = 72) in the non-obese and obese group respectively (p = 0.9). CONCLUSIONS: The TVT-O procedure is effective and safe in the long term for stress incontinence treatment, regardless of BMI.
Authors: Giacomo Novara; Walter Artibani; Matthew D Barber; Christopher R Chapple; Elisabetta Costantini; Vincenzo Ficarra; Paul Hilton; Carl G Nilsson; David Waltregny Journal: Eur Urol Date: 2010-04-23 Impact factor: 20.096
Authors: G Ghoniem; E Stanford; K Kenton; C Achtari; R Goldberg; T Mascarenhas; M Parekh; K Tamussino; S Tosson; G Lose; E Petri Journal: Int Urogynecol J Pelvic Floor Dysfunct Date: 2007-11-17
Authors: Erin A Brennand; Selphee Tang; Colin Birch; Magnus Murphy; Sue Ross; Magali Robert Journal: Int Urogynecol J Date: 2016-09-29 Impact factor: 2.894
Authors: Rosa Maria Laterza; Ksenia Halpern; Daniela Ulrich; Alexandra Graf; Karl Tamussino; Wolfgang Umek Journal: PLoS One Date: 2018-08-16 Impact factor: 3.240
Authors: Jacek K Szymański; Kornelia Zaręba; Grzegorz Jakiel; Aneta Słabuszewska-Jóźwiak Journal: Wideochir Inne Tech Maloinwazyjne Date: 2019-04-29 Impact factor: 1.195